A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)

This study will evaluate the dosimetry, safety, efficacy, pharmacokinetics (PK), pharmacodynamics and immunogenicity of CEA-PRIT 2.0 in participants with metastatic microsatellite-stable (MSS) mCRC who are intolerant to or have progressed after having received available standard-of-care (SOC) therapies.

Trial Details

NCT ID
NCT07416552
Phase
PHASE1
Sponsor
Hoffmann-La Roche
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • SPLIT Abs
  • 203Pb-DOTAM
  • 212Pb-DOTAM
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Omaha, Nebraska, United States|41.25626,-95.94043
  • Houston, Texas, United States|29.76328,-95.36327
  • Madison, Wisconsin, United States|43.07305,-89.40123

Key Eligibility Criteria

  • Histologically confirmed adenocarcinoma originating from the colon or rectum
  • Metastatic disease (Stage IV American Joint Committee on Cancer, Version 7)
  • Confirmed MSS and/or proficient mismatch repair (MMR) status
  • Experienced disease progression during or within 3 months following the last administration of systemic anti-cancer therapies for metastatic disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →